Abstract:Hot melt extrusion (HME) processed Poly (lactic-co-glycolic acid) (PLGA) implant is one of the commercialized drug delivery products, which has solid, well-designed shape and rigid structures that afford efficient locoregional drug delivery on the spot of interest for months. In general, there are a variety of material, processing, and physiological factors that impact the degradation rates of PLGA-based implants and concurrent drug release kinetics. The objective of this study was to investigate the impacts of PLGA's material characteristics on PLGA degradation and subsequent drug release behavior from the implants. Three model drugs (Dexamethasone, Carbamazepine, and Metformin hydrochloride) with different water solubility and property were formulated with different grades of PLGAs possessing distinct co-polymer ratios, molecular weights, end groups, and levels of residual monomer (high/ViatelTM and low/ ViatelTM Ultrapure). Physicochemical characterizations revealed that the plasticity of PLGA was inversely proportional to its molecular weight; moreover, the residual monomer could impose a plasticizing effect on PLGA, which increased its thermal plasticity and enhanced its thermal processability. Although the morphology and microstructure of the implants were affected by many factors, such as processing parameters, polymer and drug particle size and distribution, polymer properties and polymer-drug interactions, implants prepared with ViatelTM PLGA showed a smoother surface and a stronger PLGA-drug intimacy than the implants with ViatelTM Ultrapure PLGA, due to the higher plasticity of the ViatelTM PLGA. Subsequently, the implants with ViatelTM PLGA exhibited less burst release than implants with ViatelTM Ultrapure PLGA, however, their onset and progress of the lag and substantial release phases were shorter and faster than the ViatelTM Ultrapure PLGA-based implants, owing to the residual monomer accelerated the water diffusion and autocatalyzed PLGA hydrolysis. Even though the drug release profiles were also influenced by other factors, such as composition, drug properties and polymer-drug interaction, all three cases revealed that the residual monomer accelerated the swelling and degradation of PLGA and impaired the implant's integrity, which could negatively affect the subsequent drug release behavior and performance of the implants. These results provided insights to formulators on rational PLGA implant design and polymer selection.

Drug release mechanisms of high-drug-load, melt-extruded dexamethasone intravitreal implants

Manufacturing dexamethasone intravitreal implants: process control and critical quality attributes

Sustained Intravitreal Delivery of Dexamethasone Using an Injectable and Biodegradable Thermogel.

Protracted Intralenticular Implant of Sustained-Release Dexamethasone Implant (Ozurdex)

Modified insertion technique for a sustained-release dexamethasone intravitreal implant (Ozurdex®)

INTRAVITREALLY INJECTABLE POLY (D, L-LACTIDE) MICROSPHERES CONTAINING DEXAMETHASONE ACETATE FOR SUSTAINED RELEASE

Biodegradable dexamethasone polymer capsule for long-term release

A study of the dexamethasone sodium phosphate release properties from a periocular capsular drug delivery system

PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate

Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (ozurdex) and implant one-piece posterior capsule intraocular lens

Design and Characterization of Ocular Inserts Loaded with Dexamethasone for the Treatment of Inflammatory Ophthalmic Disease

Accelerated in vitro release testing of implantable PLGA microsphere/PVA hydrogel composite coatings.

Stability of Dexamethasone during Hot-Melt Extrusion of Filaments based on Eudragit® RS, Ethyl Cellulose and Polyethylene Oxide

Silicone matrices for controlled dexamethasone release: toward a better understanding of the underlying mass transport mechanisms

Intravitreal Administration of Dexamethasone-Loaded PLGA-TPGS Nanoparticles for the Treatment of Posterior Segment Diseases.

PLA–PCL–PEG–PCL–PLA based micelles for improving the ocular permeability of dexamethasone: development, characterization, and in vitro evaluation

Sustained zero-order release of dexamethasone after incorporation into crosslinked PEG-dendrons using click reactions

Dexamethasone Long-Term Controlled Release from Injectable Dual-Network Hydrogels with Porous Microspheres Immunomodulation Promotes Bone Regeneration

Exploring the potential of imidazolium methacrylate crosslinking with resorcinol dimethacrylate for drug delivery systems

The application of dexamethasone implants in uveitis treatment

Development of poly (lactic-co-glycolic acid) (PLGA) based implants using hot melt extrusion (HME) for sustained release of drugs: The impacts of PLGA's material characteristics